Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Leukemia & Lymphoma

Font Size

Newer Drug Helps Older Myeloma Patients

Treatment may extend survival for patients over 65, researchers say


"Transplants seem to have a clear advantage," Avigan said. But he pointed out that other drug combinations are available for myeloma, and this study tested only one.

The study also looked at the effects of "maintenance" therapy with lenalidomide (Revlimid) after patients had their transplant or combination-drug therapy. That meant taking lenalidomide pills until their cancer came back. The drug appeared to extend patients' time in remission, but not their overall survival.

Lenalidomide is already commonly used as a maintenance therapy, but there have been reservations about it, Avigan said.

It has side effects, such as infections, and some patients using it have developed second cancers, such as leukemia or lymphoma. Plus, maintenance therapy with the drug -- which costs about $160,000 a year in the United States -- hasn't yet been shown to extend patients' lives.

"But it does prolong the period of remission," Avigan said. "And for many people, that's enough."

However, many patients with myeloma aren't eligible for a stem cell transplant, including those older than 65 or 70.

"At least 50 percent of patients with newly diagnosed myeloma are considered transplant-ineligible," said Dr. Thierry Facon, the senior researcher on the second study.

In Europe, patients who can't have a transplant usually receive a particular triple-drug combination, said Facon, a hematologist at University Hospital of Lille in France.

To see whether lenalidomide plus an anti-inflammatory drug -- dexamethasone -- might work better, they recruited more than 1,600 transplant-ineligible myeloma patients. One-third were randomly assigned to 72 weeks of a standard drug combo (melphalan, prednisone and thalidomide); another third took lenalidomide/dexamethasone over 72 weeks; and the final third kept taking the drug duo until their cancer progressed.

Overall, the study found, patients fared best with continuous lenalidomide. They typically went more than 25 months with no cancer progression versus around 21 months with the other two treatments.

Their longer-term outlook was also brighter. At four years, 59 percent were still alive, compared with 56 percent of patients who received lenalidomide for only 72 weeks, and 51 percent of those given the standard drug regimen.

Today on WebMD

stem cells
What are they and why do we need them?
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Do you know the symptoms?
Vitamin D
New Treatments For Non-Hodgkins Lymphoma
Lifestyle Tips for Depression Slideshow
Pets Improve Your Health